Industry & Business

Diaceutics announces 30 jobs on back of 60% revenue growth

 Breaking News
  • Irish Distillers to Invest €150 Million in Sites in Cork and Dublin Irish Distillers has announced investment of over €150 million in its sites in Cork and Dublin to meet demand for its products as the Irish whiskey renaissance continues apace. This is accelerated by the continued growth of the company’s flagship Jameson brand, which is now in double or triple-digit growth in more than 80 markets [...]...
  • CM Precision Components Opens New Purpose-built Factory in Downpatrick Downpatrick-based CM Precision Components Ltd has officially opened its new 16,000 sq ft manufacturing facility at Invest Northern Ireland’s Killough Road Industrial Estate. The advanced engineering firm has invested almost £1 million in the construction project, to expand its production capabilities and meet the growing demands of its customers. CM Precision Components produces precision machined components for [...]...
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...
  • Government Investment in Research & Development Amounts to Over €750 Million in 2018 The latest figures on Government investment in research and development (R&D), published by the Department of Business, Enterprise and Innovation, show that over €750 million is estimated to have been invested in R&D in 2018. The data in The Research and Development Budget 2017-2018 publication is compiled from a comprehensive survey of thirty Government Departments [...]...
  • Smart Dublin in Partnership With Enterprise Ireland Award 21 New Innovation Contracts Approximately €700,000 is to be awarded to companies under Enterprise Ireland’s Small Business Innovation Research (SBIR) initiative which will enable them explore innovative solutions to address challenges faced by Local Authorities. 21 companies have been awarded Phase One funding to progress the feasibility of their solutions. Phase One funding will allow each recipient to carry [...]...

Diaceutics announces 30 jobs on back of 60% revenue growth

Diaceutics announces 30 jobs on back of 60% revenue growth
April 14
09:00 2017

Irish data insights and solutions company Diaceutics has announces 30 new jobs which will facilitate further international growth for Diaceutics and allow it to expand its presence in all of its key markets including the US, Europe, Asia and South America.

Diaceutics allows pharmaceutical companies to reach more patients that need to be on specific – and often life-saving – drugs by helping them better understand testing for specific illnesses and biomarkers. The company forecasts that the precision medicine market in which it operates will grow from €1.4 billion today to €4 billion by 2020.

Since inception, Diaceutics has been involved in more than 200 drug launches and currently has a 60% share in the top 10 global markets. It currently counts 26 out of the world’s top 30 pharmaceutical companies as clients and provides oversight of testing in 23 markets.

The 30 extra jobs over the next two years are in areas including global operations, marketing and data analysis and will bring its global team up to 100. The jobs will be created at its global headquarters in Ireland, US headquarters in Parsippany, New Jersey as well as in satellite offices in Asia and South America.

Peter Keeling, CEO, Diaceutics, said: “Testing is now at the heart of pharmaceutical companies’ ability to identify the right patients for their new therapies. We are uniquely positioned to provide the global testing perspective that allows this identification and treatment of patients who will benefit from specific and often life-saving drugs.

“To put the importance of what we do into context, we have put structures in place that each year help 48,000 cancer patients in the US and EU get biomarker testing and therefore potentially gain access to the right drug for their specific condition.

“Diaceutics has been growing by an average of 60% per annum for the past three years and we expect that growth trajectory to continue as our addressable market is doubling. To facilitate that, we will require a number of new team members in key roles over the next two years.

“Some 70% of new cancer drug launches will be diagnostics-dependent in the next five years. Pharma will be relying on us to show them how they can maximise their market share in what is going to become an increasingly profitable area – and a hugely beneficial one to patients. Diaceutics has positioned itself as a key partner for pharma as it capitalises on the unique opportunity to use diagnostics intelligence to successfully roll out precision medicine.”

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4